# Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

> **NCT02319044** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 267 (actual)

## Conditions studied

- Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

## Interventions

- **DRUG:** MEDI4736
- **DRUG:** Tremelimumab
- **DRUG:** MEDI4736 + Tremelimumab

## Key facts

- **NCT ID:** NCT02319044
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2016-09-26
- **Final completion:** 2020-07-06
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2020-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319044, "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02319044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*